Ubrogepant
Ubrogepant is an experimental drug for the treatment of migraine. It is a small-molecule calcitonin gene-related peptide receptor antagonist.[1][2]
Clinical data | |
---|---|
Other names | MK-1602 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C29H26F3N5O3 |
Molar mass | 549.554 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
References
- Tfelt-Hansen, P; Olesen, J (April 2011). "Possible Site of Action of CGRP Antagonists in Migraine". Cephalalgia: An International Journal of Headache. 31 (6): 748–50. doi:10.1177/0333102411398403. PMID 21383046.
- Spreitzer, H (22 May 2018). "Neue Wirkstoffe: Ubrogepant". Österreichische Apotheker-Zeitung (in German) (11/2018).
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.